TY - CHAP
T1 - Complex genotypic changes during failure of HBV nucleoside analogue therapy
AU - Pillay, Deenan
AU - Mutimer, David
AU - Burroughs, Nigel
AU - Cooper, David
AU - Cane, Patricia
PY - 2003/12
Y1 - 2003/12
N2 - This chapter focuses on clinical studies of hepatitis B virus (HBV) antiviral drugs and the HBV genotype. Infection in three groups of treated patients are considered-namely, (1) liver transplant recipients given HBV to prevent re-infection, (2) chronic HBV infected patients, and (3) HBV/human immunodeficiency virus-1 (HIV-1)-coinfected patients. The chapter explores the emergence of HBV drug resistance against lamivudine in a range of patient groups. A range of nucleoside analogues have activity against hepatitis B virus (HBV), including lamivudine, famciclovir, and entecavir. Differences in the dynamics of emergence of resistance between transplant and non-transplant patients have been identified through detailed virological monitoring and genotypic analysis of HBV polymerase. The monotherapy drug pressure selects for a wide range of viral species, the presence of which compromise subsequent nucleoside analogue therapy. It is essential that the new strategies for therapy of HBV are based on highly potent combination regimens, thereby reducing the risk of emergence of drug resistance.
AB - This chapter focuses on clinical studies of hepatitis B virus (HBV) antiviral drugs and the HBV genotype. Infection in three groups of treated patients are considered-namely, (1) liver transplant recipients given HBV to prevent re-infection, (2) chronic HBV infected patients, and (3) HBV/human immunodeficiency virus-1 (HIV-1)-coinfected patients. The chapter explores the emergence of HBV drug resistance against lamivudine in a range of patient groups. A range of nucleoside analogues have activity against hepatitis B virus (HBV), including lamivudine, famciclovir, and entecavir. Differences in the dynamics of emergence of resistance between transplant and non-transplant patients have been identified through detailed virological monitoring and genotypic analysis of HBV polymerase. The monotherapy drug pressure selects for a wide range of viral species, the presence of which compromise subsequent nucleoside analogue therapy. It is essential that the new strategies for therapy of HBV are based on highly potent combination regimens, thereby reducing the risk of emergence of drug resistance.
UR - http://www.scopus.com/inward/record.url?scp=84902051490&partnerID=8YFLogxK
U2 - 10.1016/B978-044450986-4/50080-1
DO - 10.1016/B978-044450986-4/50080-1
M3 - Chapter
AN - SCOPUS:84902051490
SN - 9780444509864
SP - 353
EP - 364
BT - Frontiers in Viral Hepatitis
PB - Elsevier Inc.
ER -